muscle-invasive bladder cancer
Oncology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| durvalumab Perioperative treatment (neoadjuvant and adjuvant) of patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based neoadjuvant… | Nov 2025 | Recommended with restriction | input received Medical Oncology Group Australia · Rare Cancers Australia · BEAT Bladder Cancer Australia |
Who spoke
Medical Oncology Group Australia · Rare Cancers Australia · BEAT Bladder Cancer Australia
What the PBS pays
$176M in government benefit over 2024–25, across 16,460 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| durvalumab | $175.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| durvalumabDurvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer | TA1138 | recommended restricted | 2026-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.